Metformin I a hypoglycemic drug, biguanide. Reduces both basal and postprandial glycemia. Metformin does not stimulate insulin secretion and therefore does not cause hypoglycemia.
Metokred 501: each film-coated tablet contains:
Glimepiride USP 1 mg;
Metformin Hydrochloride USP 500 mg;
Excipients q.s.
Permitted dyes are used for shells.
Metokred 502: each film-coated tablet contains:
Glimepiride USP 2 mg;
Metformin Hydrochloride USP 500 mg;
Excipients q.s.
Permitted dyes are used for shells.
Treatment for type 2 diabetes, in addition to diet and exercise:
– in case of inefficiency of monotherapy with glimepiride or metformin;
– to replace combination therapy consisting of glimepiride and metformin.
The dosage regimen is set individually, taking into account the level of glucose in the blood.
As a rule, it is recommended to start treatment with the lowest effective dose and, depending on the level of glucose in the blood, increase the dose. In this case, appropriate monitoring of blood glucose levels should be carried out. The drug should be prescribed 1 or 2 times a day, before or during meals.
